Biogen Inc (BIIB)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $37.46B
Last updated: Nov 17, 2026 at 11:04 AM ET
Biogen Inc (BIIB) Financials: Revenue, Profit and Cash Flow
Biogen reported revenue of $9.89B for the fiscal year ended Dec 31, 2025, up 2.2% from the year before. That year, net income was $1.29B with a net margin of 13.1%, operating cash flow was $2.20B and free cash flow was $2.05B. The quarter ended Sep 30, 2026 had revenue of $2.80B and net income of -$20.60M.
Revenue and Margins
The operating margin was 15.7% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $11.45B, a compound annual decline of 1.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $9.89B | +2.2% | 75.7% | 15.7% | 13.1% |
| Dec 2024 | $9.68B | -1.6% | 76.1% | 19.7% | 16.9% |
| Dec 2023 | $9.84B | -3.3% | 74.2% | 13.2% | 11.8% |
| Dec 2022 | $10.17B | -7.4% | 77.6% | 34.2% | 29.1% |
| Dec 2021 | $10.98B | -18.3% | 80.8% | 25.9% | 15.7% |
| Dec 2020 | $13.44B | -6.5% | 86.6% | 33.8% | 30.2% |
| Dec 2019 | $14.38B | +6.9% | 86.4% | 49.0% | 41.0% |
| Dec 2018 | $13.45B | +9.6% | 86.5% | 43.8% | 33.3% |
| Dec 2017 | $12.27B | +7.2% | 86.7% | 43.6% | 21.8% |
| Dec 2016 | $11.45B | N/A | 87.1% | 45.0% | 32.3% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 20.9% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B |
| Cost of revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B | $1.63B | $1.48B |
| Gross profit | $7.49B | $7.37B | $7.30B | $7.90B | $8.87B | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B |
| Research and development | $2.25B | $2.04B | $2.46B | $2.23B | $2.52B | $4.07B | $2.28B | $2.71B | $2.37B | $1.97B |
| Operating income | $1.56B | $1.91B | $1.30B | $3.48B | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B |
| Net income | $1.29B | $1.63B | $1.16B | $2.96B | $1.73B | $4.06B | $5.89B | $4.47B | $2.67B | $3.70B |
| EBITDA | $2.58B | $2.81B | $1.82B | $4.11B | N/A | $5.50B | $7.59B | $6.55B | $6.21B | $5.62B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.80B | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | $2.43B | $2.45B | $2.47B | $2.46B | $2.29B | $2.39B |
| Gross profit | $2.06B | $1.96B | $1.82B | $1.78B | $1.86B | $2.04B | $1.80B | $1.87B | $1.83B | $1.92B | $1.75B | $1.77B |
| Operating income | -$9.00M | $132.40M | $377.70M | -$69.20M | $557.30M | $757.20M | $311.20M | $291.50M | $451.00M | $698.70M | $464.80M | $291.60M |
| Net income | -$20.60M | $97.50M | $319.50M | -$62.10M | $466.50M | $648.00M | $240.50M | $266.70M | $388.50M | $583.60M | $393.40M | $248.90M |
Balance Sheet
As of Dec 2025, total debt of $6.29B exceeded cash and equivalents by $3.28B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B |
| Current assets | $8.97B | $7.46B | $6.86B | $9.79B | $7.86B | $6.89B | $8.38B | $7.64B | $7.87B | $8.73B |
| Cash and equivalents | $3.01B | $2.38B | $1.05B | $3.42B | $2.26B | $1.33B | $2.91B | $1.22B | $1.57B | $2.33B |
| Total liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B | $13.93B | $13.90B | $12.26B | $11.05B | $10.75B |
| Short-term debt | $0 | $1.75B | $150.00M | $0 | $999.10M | $0 | $1.50B | $0 | $3.20M | $4.70M |
| Long-term debt | $6.29B | $4.55B | $6.79B | $6.28B | $6.27B | $7.43B | $4.46B | $5.94B | $5.93B | $6.51B |
| Shareholder equity | $18.26B | $16.72B | $14.80B | $13.40B | $10.90B | $10.70B | $13.34B | $13.04B | $12.61B | $12.14B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $32.05B | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | $26.84B |
| Total liabilities | $13.13B | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B | $11.33B | $11.95B | $10.91B | $11.35B | $12.05B |
| Cash and equivalents | $1.30B | $1.28B | $3.38B | $3.01B | $3.86B | $2.76B | $2.60B | $2.38B | $1.70B | $1.91B | $1.07B | $1.05B |
| Shareholder equity | $18.92B | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B | $16.72B | $16.36B | $15.89B | $15.21B | $14.80B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 93.2% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B | $4.23B | $7.08B | $6.19B | $4.55B | $4.59B |
| Capital expenditures | $153.80M | $153.70M | $277.00M | $240.30M | $258.10M | $424.80M | $814.50M | $2.27B | $2.07B | $1.82B |
| Free cash flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B | $3.81B | $6.26B | $3.92B | $2.48B | $2.77B |
| Dividends paid | $0 | $0 | $12.30M | $12.40M | $94.40M | $71.00M | $4.30M | $36.40M | $436.80M | $0 |
| Share repurchases | N/A | N/A | N/A | $750.00M | $1.80B | $6.68B | $5.87B | $4.35B | $1.37B | $1.00B |
| Investing cash flow | -$1.37B | -$799.20M | -$4.10B | $1.58B | -$563.70M | -$608.60M | $470.50M | -$2.05B | -$2.96B | -$2.48B |
| Financing cash flow | -$301.90M | -$683.50M | $149.30M | -$1.75B | -$2.09B | -$5.27B | -$5.86B | -$4.47B | -$2.38B | -$1.05B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $640.80M | $448.90M | $645.50M | $511.90M | $1.27B | $160.90M | $259.30M | $760.90M | $935.60M | $625.80M | $553.20M | $12.50M |
| Capital expenditures | $40.40M | $40.90M | $51.20M | $43.90M | $46.20M | $26.60M | $37.10M | $39.30M | $35.00M | $33.50M | $45.90M | $65.20M |
| Free cash flow | $600.40M | $408.00M | $594.30M | $468.00M | $1.23B | $134.30M | $222.20M | $721.60M | $900.60M | $592.30M | $507.30M | -$52.70M |
Frequently Asked Questions About BIIB
What is Biogen's annual revenue?
Biogen reported revenue of $9.89B for the fiscal year ended Dec 31, 2025.
How fast is Biogen's revenue growing?
Revenue was up 2.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.9%.
Is Biogen profitable?
Yes. Biogen reported net income of $1.29B for the fiscal year ended Dec 31, 2025, with a net margin of 13.1%.
How much free cash flow does BIIB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $2.20B minus capital expenditures of $153.80M produced free cash flow of $2.05B.
How much debt does Biogen have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $6.29B, short-term debt of $0 and cash and equivalents of $3.01B.
BIIB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors